Hikma Pharmaceuticals PLCShs Aktie
| 23,20EUR | 1,40EUR | 6,42% |
WKN: A0HG69 / ISIN: GB00B0LCW083
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 69,47 |
| Darhold Ltd. | 27,04 |
| Wellington Management Co. LLP | 5,21 |
| BlackRock Advisors (UK) Ltd. | 2,77 |
| The Vanguard Group, Inc. | 2,67 |
| Vanguard Health Care Fund | 2,45 |
| Mawer Global Small Cap Fund | 1,96 |
| Government Pension Fund - Global (The) | 1,79 |
| Capital Research & Management Co. (World Investors) | 1,44 |
| Royal London Asset Management Ltd. | 1,41 |
| Employees Provident Fund Board | 1,30 |
| Norges Bank Investment Management | 1,18 |
| Mawer Investment Management Ltd. | 1,17 |
| BlackRock Investment Management (UK) Ltd. | 1,13 |
| PUTM ACS UK All Share Listed Equity Multi Manager Fund | 1,09 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8 600 | 8 600 | 8 700 | 8 800 | 9 100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,20 | 0,21 | 0,21 | 0,23 | 0,25 |
Bilanz (in Mio. GBP) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 395 | 1 406 | 1 546 | 1 662 | 1 647 |
| Summe Anlagevermögen | 1 572 | 1 619 | 1 682 | 2 055 | 2 024 |
| Summe Aktiva | 2 967 | 3 025 | 3 228 | 3 717 | 3 671 |
Bilanz (in Mio. GBP) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1 360 | 1 454 | 1 406 | 1 931 | 1 938 |
| Summe Eigenkapital | 1 607 | 1 571 | 1 821 | 1 786 | 1 733 |
| Summe Passiva | 2 967 | 3 025 | 3 228 | 3 717 | 3 671 |
Adresse
| 1 New Burlington Place, W1S 2HR London | |
| Telefon | +44 (20) 7399-2760 |
| Fax | +44 (20) 7399-2761 |
| Internet | http://www.hikma.com |
Management
|
Bassam Wael Rushdi Kanaan
Executive Vice President-Corporate Development |
|
Cynthia L. Flowers
Independent Non-Executive Director |
|
Deneen Vojta
Independent Non-Executive Director |
|
Douglas Malcolm Hurt
Independent Non-Executive Director |
|
Hafrun Fridriksdottir
President-Generics Business |
|
Helen Middlemist
Group Secretary |
|
Hill Julie
SVP-Corporate Quality Compliance, Health & Safety |
|
Hussein Arkhagha
Chief People Officer |
|
John J. Castellani
Independent Non-Executive Director |
|
Khalid Walid Hosni Nabilsi
Chief Financial Officer |
|
Kristy Ronco
Executive VP-Sales & Marketing |
|
Laura Mihaela Balan
Independent Non-Executive Director |
|
Majda Labadi
Executive VP-Organizational Development |
|
Mary Regina Henderson
Independent Non-Executive Director |
|
Mohammed Ali Khaldoun Al-Husry
Non-Executive Director |
|
Riad Mishlawi
Chief Executive Officer & Director |
|
Said Samih Taleb Darwazah
Executive Chairman |
|
Susan Ringdal
Executive VP-Strategic Planning & Global Affairs |
|
Victoria Mary Hull
Senior Independent Non-Executive Director |
|
William C. Larkins
President-Injectables Business |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
